Reported Earlier Intellia Therapeutics To Present Data From The Phase 2 Study Of NTLA-2002 For The Treatment Of Hereditary Angioedema At The 2024 ACAAI Annual Scientific Meeting; To Host Investor Webcast On October 28, At 8:00 A.m. ET
Reported Earlier Intellia Therapeutics To Present Data From The Phase 2 Study Of NTLA-2002 For The Treatment Of Hereditary Angioedema At The 2024 ACAAI Annual Scientific Meeting; To Host Investor Webcast On October 28, At 8:00 A.m. ET
- First presentation of detailed Phase 2 results following previous positive topline announcement that study of NTLA-2002 met primary and all secondary endpoints
- Intellia to host investor webcast on Monday, October 28, at 8:00 a.m. ET
- 此前，NTLA-2002的研究達到了主要和所有次要終點，併發布了積極的總結結果，此次是首次詳細呈現第2階段結果。
- Intellia將在10月28日上午8點（東部時間）舉辦投資者網絡研討會。
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that data from the Phase 2 study of NTLA-2002 will be presented at the 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, taking place October 24 – 28 in Boston, Massachusetts. NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for hereditary angioedema (HAE), a rare genetic condition that leads to potentially life-threatening swelling attacks.
美國麻省劍橋，2024年9月12日（全球新聞社）——Intellia Therapeutics, Inc.（納斯達克:NTLA）是一家領先的臨床階段基因編輯公司，專注於利用CRISPR技術革新醫學。今天宣佈，NTLA-2002的第2階段研究數據將在2024年美國變態反應、哮喘與免疫學（ACAAI）年度科學會議上發佈，該會議將於10月24日至28日在馬薩諸塞州波士頓舉行。NTLA-2002是一種調查性體內CRISPR基因編輯療法，用於治療遺傳性血管性水腫（HAE），這是一種罕見的基因性疾病，可能導致生命威脅的腫脹發作。
譯文內容由第三人軟體翻譯。
